Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPI-006 · 2 trials · 14 indications
Incidence of adverse events (including serious adverse events and dose limiting toxicities).
Measure changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.
| Arm | Type | Description |
|---|---|---|
| CPI-006 Dose Escalation | EXPERIMENTAL | CPI-006 + Standard of Care |
| Control Arm | OTHER | Standard of Care Only |
| Cohort 1a | EXPERIMENTAL | CPI-006 |
| Cohort1b | EXPERIMENTAL | CPI-006 + ciforadenant |
| Cohort 1c | EXPERIMENTAL | CPI-006 + pembrolizumab |
| Cohort 2a | EXPERIMENTAL | CPI-006 |
| Cohort 2b | EXPERIMENTAL | CPI-006 + ciforadenant |
| Cohort 2c | EXPERIMENTAL | CPI-006 + pembrolizumab |
| Name | Type | Description |
|---|---|---|
| CPI-006 | DRUG | Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care. |
| Standard of Care | OTHER | Participants will receive standard of care treatment only. |
| CPI-006 + ciforadenant | DRUG | Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression. |
| CPI-006 + pembrolizumab | DRUG | Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression. |
Inclusion Criteria: * Nasal swab test positive by reverse transcriptase PCR for SARS CoV-2 within past 7 days, and onset of COVID-19 symptoms no more than 10 days prior to the positive test * Hospitalized and have stable mild to moderate symptoms of COVID-19 * Blood oxygen saturation of a minimum o...
Top 9 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | ibuzatrelvir, Nirmatrelvir/ ritonavir, BNT162b2/RIV |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Molnupiravir |
| Invivyd, Inc. | IVVD | 2 | PHASE3 | VYD2311 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Tradipitant |
| Moderna, Inc. | MRNA | 2 | PHASE2 | mRNA-1283, mRNA-1273 |
| ImmunityBio Inc | IBRX | 2 | PHASE2 | Nogapendekin alfa inbakicept |
| Traws Pharma, Inc. | TRAW | 1 | PHASE2 | Ratutrelvir |
| GeoVax Labs, Inc. | GOVX | 1 | PHASE2 | GEO-CM04S1 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE2 | Remdesivir |
CPI-006 is an investigational small molecule developed by Corvus Pharmaceuticals, Inc. (ticker CRVS). It has been studied as an immunotherapy in hospitalized COVID-19 patients and in patients with advanced solid tumors and blood cancers, including non-small cell lung cancer. It remains in Phase 1 clinical development.
CPI-006 targets CD73, a protein target. CD73 is an enzyme involved in adenosine signaling, and blocking it is intended to support immune responses against disease. Corvus Pharmaceuticals developed CPI-006 as a small molecule directed at this CD73 protein target.
CPI-006 is developed by Corvus Pharmaceuticals, Inc., which trades under the ticker CRVS. The company sponsored the Phase 1 studies of CPI-006 in hospitalized COVID-19 patients and in patients with advanced cancers.
CPI-006 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. Both of its recorded Phase 1 trials, one in COVID-19 and one in advanced cancers, are listed as completed.
CPI-006 has been studied in two completed Phase 1 trials. NCT04464395 evaluated CPI-006 as immunotherapy for hospitalized COVID-19 patients and enrolled 30 participants in the United States. NCT03454451 studied CPI-006 alone and in combination with ciforadenant and with pembrolizumab in patients with advanced cancers, enrolling 117 participants across the United States and Australia.
CPI-006 was studied in Phase 1 as a treatment for non-small cell lung cancer and other advanced cancers. Trial NCT03454451 evaluated CPI-006 alone and in combination with ciforadenant and with pembrolizumab in patients with advanced cancers, including non-small cell lung cancer. It is investigational and not approved.